Migraine is a chronic medical condition affecting an estimated 38 million people in the United States.  Throbbing, often one-sided moderate-to-severe head pain, accompanied by light and sound sensitivity and nausea/vomiting are the most common symptoms.  Some migraine sufferers experience dizziness, visual symptoms, numbness or weakness on one side of the body, slowed thinking or trouble speaking.

Migraine predominantly effects young and middle-aged woman (that is, during their prime work and child-rearing years), though it can strike men and children as well. When untreated, the World Health Organization lists migraine as among the top ten most disabling medical conditions.

Our Migraine Prevention Program aims to find better acute and preventive treatments for patients who suffer from migraine.

This is a FREE service offered to our patients. Health insurance is not needed. Medical care, office visits, and medication are at no cost to you. Patients are also paid for their participation to compensate for time and travel.

Current studies now enrolling:

  • Tian/Tx360: This study is for patients who experience 15 or more headache days per month and prefer an alternative to pills or injections. The Tx360 is a nasal application device with a small, soft catheter that is placed into the nose in order to spray a small amount of FDA approved medication onto a pain nerve bundle called the SPG. The SPG is located between the nose and brain and its activation has been found to be associated with migraines.
    Read more here.
  • Biohaven/BHV 3000: This study showcases a (potentially) big product: a CGRP oral medication for the treatment of acute migraine. CGRP is an inflammatory molecule in the brain that has been found to trigger migraines. There are several CGRP blocking medications that are currently FDA approved and available to patients through their healthcare providers. However, these are only available as injections, whereas many patients may prefer taking an oral medication. This study also hosts the benefit of an open-label phase where all eligible patients will be guaranteed to receive the migraine preventative medication. You may qualify for this study if you have 2-14 headache days per month.
    Read more here.

To learn more about our FREE Migraine Prevention Program available to our patients at CCHNC or to determine your eligibility for participation, please contact our clinical research coordinator via call, text, or email:

Christina Haydel
Christina@neinh.com
504-418-6040